Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 171-176 , February 2008

Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET

  • Tatsuro Tsuchida

      Affiliations

    • Department of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 776 61 3111x2335; fax: +81 776 61 8137.
    • ,
  • Hiroaki Takeuchi

      Affiliations

    • Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Hidehiko Okazawa

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Tetsuya Tsujikawa

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan
    • ,
  • Yasuhisa Fujibayashi

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan

Received 27 August 2007 ,Revised 17 October 2007 ,Accepted 7 November 2007.

References 

  1. Gambhir SS, Czermin J, Schwimmer J, Silvermann DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(Suppl):1S–71S
  2. Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med. 1991;32:616–622
  3. DiChiro G. Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol. 1986;22:360–371
  4. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005;181:483–499
  5. Wong TZ, Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12:615–626
  6. Spence AM, Mankoff DA, Muzi M. Positron emission tomography imaging of brain tumors. Neuroimag Clin N Am. 2003;13:717–739
  7. Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, et al. Clinical positron emission tomography for brain tumors: comparison of fluorodeoxyglucose F-18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol. 1996;17:345–353
  8. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–785
  9. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukushima T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998;25:1261–1269
  10. Ohtani T, Kurihara H, Ishiguchi S, Saito N, Oriuchi N, Inoue T, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001;28:1664–1670
  11. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Cahng CW, et al. PET imaging of brain astrocytoma with1-11C acetate. Eur J Nucl Med Mol Imaging. 2006;33:420–427
  12. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:114–122
  13. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. World Health Organization international classification of tumors. Berlin: Springer; 1993;
  14. DeGrado TR, Turkington TG, Willimas JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of whole-body PET scanner. J Nucl Med. 1994;35:1398–1406
  15. Kihlberg T, Valind S, Langstom B. Synthesis of [1-11C], [2-11C], [1-11C](2H3) and [2-11C](2H3) acetate for in vivo studies of myocardium using PET. Nucl Med Biol. 1994;21:1067–1072
  16. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carried-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–238
  17. Dienel GA, Popp D, Drew PD, Ball K, Krisht A, Cruz NF. Preferential labeling of glial and meningial brain tumors with [2-14C]acetate. J Nucl Med. 2001;42:1243–1250
  18. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET?. Eur J Nucl Med. 1999;26:1501–1509
  19. Patano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser MG, Comar D. Regional cerebral blood flow and oxygen consumptions in human aging. Stroke. 1984;15:635–641
  20. Martin AJ, Friston KJ, Colebatch JG, Frackowiak RS. Decrease in regional cerebral blood flow with normal aging. J Cereb Blood Flow Metab. 1991;11:684–689
  21. Greenberg HS, Chandler WF, Sandler HM. In: Brain tumors. New York: Oxford University Press; 1999;p. 58–77
  22. Waniewski RA, Martin DL. Preferential utilization of acetate by astrocytes is attributable to transport. J Neurosci. 1998;18:5225–5233
  23. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998;49:436–440

PII: S0969-8051(07)00279-X

doi: 10.1016/j.nucmedbio.2007.11.004

Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 171-176 , February 2008

Article Tools

* Image Usage & Resolution